The Next Generation Genome Editing Market Size is predicted to develop with a CAGR of 21.8% during the forecast period for 2024-2031.
The Next Generation Genome Editing market is rapidly advancing with technologies that enhance the capabilities of CRISPR-Cas9, addressing its limitations and expanding its potential. These advancements provide improved precision, efficiency, and the ability to make large-scale DNA modifications. Key innovations include Bridge RNA, which facilitates large-scale insertions and rearrangements, and engineered Cas9 variants that enhance activity, broaden target ranges, and reduce immunogenicity.
The applications of these next-generation tools span various fields, including basic and clinical research for studying diseases like sickle cell and cancer, therapeutics for genetic and viral conditions, agriculture for developing resilient crops, and environmental applications for remediation and conservation. The market's growth is driven by the pursuit of more refined and versatile genetic engineering tools, as researchers seek to overcome the limitations of existing technologies, such as off-target effects and scalability challenges.
Competitive Landscape
Some of the Key Players in Next Generation Genome Editing Market:
- Addgene
- Beam Therapeutics
- Bio Palette Co., Ltd
- Caribou Biosciences
- Cellectis
- Creative Biogene
- CRISPR Therapeutics.
- Danaher Corporation
- EdiGene, Inc.
- Editas Medicine
- ElevateBio
- GenKOre
- GenScript
- Horizon Discovery Ltd.
- Inscripta, Inc
- Integrated DNA Technologies (IDT)
- Intellia Therapeutics
- KromaTiD, Inc
- Maravai LifeSciences
- Merck KGaA
- Pairwise
- Precision BioSciences
- ProQR Therapeutics
- QI-Biodesign
- Recombinetics
- Revvity
- Sangamo Therapeutics, Inc.
- Scribe Therapeutics
- Shape TX
- Synthego
- Synthorx (part of Sanofi)
- Other Prominent Players
Market Segmentation:
The next generation genome editing market is segmented by type of gene editing technique, application area, type of end user. By type of gene editing technique, the market is segmented recombinase-based editing, prime genome editing, bridge editing, base editing, retron library recombineering (RLR), transposon-based systems, homology-directed repair (HDR), and other emerging technologies. By application area market is categorized into drug discovery and development, diagnostics. By type of end user, the market is categorized into biotechnology companies, academic institutions, government laboratories, contract research organizations.
Base Editing is Expected to Drive the Next Generation Genome Editing Market
Base editing is significantly driving the Next Generation Genome Editing market due to its precision and safety advantages over traditional gene editing methods. This innovative technique allows for targeted alterations of single nucleotide bases in the DNA sequence without creating double-stranded breaks, which are common in other CRISPR-based methods. Ongoing advancements in base editing technologies, such as the development of modular systems for multiplex editing, are enhancing its applicability across fields like oncology, cardiology, and regenerative medicine. Companies are actively investing in base editing platforms to optimize research capabilities and therapeutic outcomes, which is expected to fuel market growth.
The Drug Discovery and Development Segment is Growing at the Highest Rate in the Next Generation Genome Editing Market.
The Drug Discovery and Development segment within the Next Generation Genome Editing market is growing rapidly due to technological advancements, increased investment, and the rise of personalized medicine. CRISPR's simplicity and cost-effectiveness have revolutionized drug discovery by allowing efficient, targeted edits, accelerating the identification of drug targets and development of new therapies. Significant funding from public and private sectors supports research for novel treatments of genetic disorders and complex diseases. The segment also benefits from numerous clinical trials and the shift towards personalized medicine, enabling tailored therapies for individual genetic mutations, especially in oncology and rare genetic disorders.
Regionally, North America Led the Next Generation Genome Editing Market.
North America's next generation genome editing market is boosted by a strong research infrastructure, high investment levels, and the presence of major industry players. The region's robust research ecosystem, comprising leading academic institutions and organizations, supports extensive R&D in genome editing, driving innovation and commercialization. Significant public and private investments, including government funding from agencies like the NIH, advance genome editing projects. Additionally, leading companies such as CRISPR Therapeutics, and Editas Medicine are at the forefront of developing and commercializing innovative CRISPR-based technologies, which are widely adopted in drug discovery and development.
Next Generation Genome Editing Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 21.8 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of Gene Editing Technique, Application Area, Type of End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Addgene, Beam Therapeutics, Bio Palette Co., Ltd, Caribou Biosciences, Cellectis, Creative Biogene, CRISPR Therapeutics, Danaher Corporation, EdiGene, Inc., Editas Medicine, ElevateBio, GenKOre, GenScript, Horizon Discovery Ltd., Inscripta, Inc, Integrated DNA Technologies (IDT), Intellia Therapeutics, KromaTiD, Inc, Maravai LifeSciences, Merck KGaA, Pairwise, Precision BioSciences, ProQR Therapeutics, QI-Biodesign, Recombinetics, Revvity, Sangamo Therapeutics, Inc., Scribe Therapeutics, Shape TX, Synthego, Synthorx (part of Sanofi) |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
